Results 221 to 230 of about 269,130 (350)
Induction of remission with oral budesonide MMX® (9 mg) tablets in oatients with mild to moderate, active Ulcerative Colitis: A multicenter, open-label efficacy and safety study [PDF]
Simon Travis +4 more
openalex +1 more source
Abstract Primary eosinophilic gastrointestinal disorders beyond the esophagus (EGIDs) are rare, predominantly Th2‐mediated inflammatory conditions, affecting various segments of the gastrointestinal tract. We report the case of a 12‐year‐old boy with recurrent abdominal pain, peripheral eosinophilia, and progressive gastritis, duodenitis, and enteritis
Almudena Sánchez‐Ramírez +6 more
wiley +1 more source
Comparative Effectiveness and Safety of Upadacitinib and Vedolizumab in Biologic‐Experienced Patients With Ulcerative Colitis: A Retrospective Study [PDF]
Neta Sror +6 more
openalex +1 more source
Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Christina Low Kapalu +3 more
wiley +1 more source
Abstract Objectives We aimed to summarise findings on blood cytokine levels in patients with paediatric‐onset inflammatory bowel disease (PIBD) compared to healthy controls. Methods This systematic review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guidelines and was registered at Prospero (CRD42024579684 ...
Sabine Jansson +7 more
wiley +1 more source
MicroRNAs as multifaceted regulators and therapeutic targets in ulcerative colitis. [PDF]
Wang X, Jiang N, Yin W, Cui X.
europepmc +1 more source
Abstract Objective Multidisciplinary care is recommended for pediatric inflammatory bowel disease (IBD). This study aims to describe provider attitudes, barriers, and facilitators regarding multidisciplinary care in pediatric IBD, and explore associations between multidisciplinary care access and center‐level factors.
Nicole Davidson +6 more
wiley +1 more source
Study on the effect of modified diosmetin for ulcerative colitis. [PDF]
Liu Y +10 more
europepmc +1 more source
Abstract Ustekinumab (UST) is a monoclonal antibody used in the management of moderate to severe inflammatory bowel disease. While generally well‐tolerated, serious adverse reactions, including hypersensitivity and anaphylaxis, have been documented, specifical following the initial intravenous (IV) dose.
Kennedy Sparling +2 more
wiley +1 more source

